Bamocaftor

DB15177InvestigationalSmall molecule

Bamocaftor (VX-659) is under investigation in clinical trial NCT03224351 (A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis).

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₂₈H₃₂F₃N₅O₄S · 591.65 g/mol (avg)
Code names: VX-659

Resolves to

Compound

UNII8C7XEW3K7SCAS2204245-48-5ChEMBLCHEMBL4297849

Structure

InChIKeyIGEOJNMYRZUKIK-IBGZPJMESA-NSMILESC[C@@H]1CN(C2=C(C=CC(=N2)N2C=CC(OCCC3(CC3)C(F)(F)F)=N2)C(=O)NS(=O)(=O)C2=CC=CC=C2)C(C)(C)C1

Targets

P13569CFTR

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bamocaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account